A strain of Burkholderia glanders and its application

CN118620800BActive Publication Date: 2024-11-12CHINA INST OF VETERINARY DRUG CONTROL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411084031.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-12
Estimated Expiration
2044-08-08

AI Technical Summary

Technical Problem

[0005]目前没有用于人或马的鼻疽病疫苗和诊断试剂,而且人患病后可供使用的抗生素极少,治疗周期较长且效果不佳,尽管在早期通过积极的联合抗生素治疗可以部分治愈,但未经治疗的人可能会出现高达40%的死亡率

Benefits of technology

[0040]1、本发明成功筛选出一株具有良好免疫原性的天然弱毒鼻疽伯克霍尔德氏菌(Burkholderia mallei)CVCC67001。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118620800B_ABST
    Figure CN118620800B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of veterinary biological products, and in particular to a Burkholderia glanders strain and its application. The Burkholderia glanders strain is named CVCC67001, and its deposit number is: CGMCC No.27409. The live Burkholderia glanders bacterial preparation prepared by the Burkholderia glanders strain CVCC67001 of the present invention has good safety, immunogenicity and efficacy, and the extracted and purified LPS is used as a coating antigen to establish an iELISA method with good antigenicity, and after immunizing mice as a vaccine candidate strain, it shows an immune protection effect of 80%-100%.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of veterinary biological products, and in particular to a Burkholderia glanders strain and a preparation method and application thereof. Background Art

[0002] Glanders is an acute, explosive zoonotic infectious disease caused by the bacterium Burkholderia mallei.

[0003] Glanders is a notifiable disease of the World Organization for Animal Health, and horses are more susceptible. The disease mainly attacks the respiratory system, lymphatic system and skin of adult horses, causing specific scars in the tracheal mucosa, nasal cavity, larynx or skin, and glandery-like nodules in the lymph nodes, lungs and other solid organs. The disease is not seasonal and can be transmitted through food, aerosols or skin, and can be transmitted between animals and between animals and humans, but transmission between humans is relatively rare.

[0004] Because the disease is fatal and contagious to humans, Burkholderia glanders is listed as a Class B biological threat agent by the U.S. Centers for Disease Control and Prevention (CDC). my country urgently needs to develop glanders diagnostic reagents and vaccines as strategic reserve materials to provide technical support for the prevention and control of glanders.

[0005] There is currently no vaccine or diagnostic test for glanders for humans or horses, and there are very few antibiotics available for use in humans. Treatment cycles are long and ineffective, and although it can be partially cured through aggressive combination antibiotic treatment in the early stages, untreated humans may have a mortality rate of up to 40%.

[0006] The invention uses a natural attenuated strain of Burkholderia mallei isolated and selected from horse tissues suffering from glanders. The strain is Gram-negative, non-motile, and has a genome size of 5.78M. LPS extracted and purified from Burkholderia mallei is used as a coating antigen to establish an iELISA method with good antigenicity. After Burkholderia mallei is used as a vaccine candidate strain to immunize mice, it shows an immune protection effect of 80%-100%. Summary of the invention

[0007] The technical problem to be solved by the present invention is to provide a Burkholderia mallei strain.

[0008] The Burkholderia mallei strain was named CVCC67001 and was deposited in the General Microbiology Center of China Culture Collection Administration on May 22, 2023. The deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and its deposit number is CGMCC NO.27409.

[0009] The present invention also provides a preparation, characterized in that the strain of the preparation comprises a Burkholderia mallei strain;

[0010] Furthermore, the Burkholderia mallei strain is a strain with a deposit number of CGMCC NO.27409.

[0011] Furthermore, the Burkholderia mallei strain and the preparation thereof of the present invention may be in a form for systemic administration;

[0012] Furthermore, the method for administering the Burkholderia mallei strain and the preparation thereof of the present invention comprises administering the strain or the preparation to an animal;

[0013] Preferably, the method for administering the Burkholderia mallei strain and its preparation of the present invention comprises administering the strain or preparation to equine animals such as horses, donkeys and mules;

[0014] More preferably, the Burkholderia mallei strains and preparations thereof of the present invention may be formulated and / or packaged for administration in a single dose or multiple dose regimen.

[0015] The present invention also provides the use of the Burkholderia mallei strain and the preparation thereof in the preparation of a Burkholderia mallei vaccine;

[0016] Furthermore, the Burkholderia mallei strain is a strain with a deposit number of CGMCC NO.27409.

[0017] The present invention also provides the use of the Burkholderia mallei strain and the preparation thereof in preparing a drug for preventing and treating diseases caused by Burkholderia mallei;

[0018] Furthermore, the Burkholderia mallei strain is a strain with a deposit number of CGMCC NO.27409.

[0019] The present invention also provides the use of the Burkholderia mallei strain and the preparation thereof in preparing reagents for differential diagnosis of diseases caused by Burkholderia mallei;

[0020] Furthermore, the Burkholderia mallei strain is a strain with a deposit number of CGMCC NO.27409.

[0021] The present invention also provides a method for eliciting a protective immune response against Burkholderia mallei in an animal, comprising administering Burkholderia mallei and a preparation thereof to the animal;

[0022] Furthermore, the Burkholderia mallei strain is a strain with a deposit number of CGMCC NO.27409.

[0023] The present invention also provides a method for eliciting a protective immune response against Burkholderia mallei in an animal, comprising administering Burkholderia mallei to a horse;

[0024] Furthermore, the Burkholderia mallei strain is a strain with a deposit number of CGMCC NO.27409.

[0025] The present invention also provides an iELISA method for detecting Burkholderia mallei disease, which comprises extracting lipopolysaccharide from Burkholderia mallei as a coating antigen;

[0026] Furthermore, the Burkholderia mallei strain is a strain with a deposit number of CGMCC NO.27409.

[0027] Furthermore, the P / N value is greater than or equal to 10, and can be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more.

[0028] The present invention also provides a method for extracting lipopolysaccharide from Burkholderia mallei, characterized in that the lipopolysaccharide is extracted by heat treating Burkholderia mallei with phenol;

[0029] Further, the method comprises:

[0030] (1) Centrifuge and discard the supernatant to obtain the bacterial cells.

[0031] (2) After suspending and heating in double distilled water, add phenol and stir.

[0032] (3) After absorbing the phenol phase, add methanol containing saturated sodium acetate and let it stand for a while, then discard the supernatant.

[0033] (4) Add double distilled water, stir, centrifuge and collect the supernatant.

[0034] (5) Nuclease and proteinase K were added for digestion.

[0035] (6) Obtain lipopolysaccharide (LPS) after dialysis with deionized water;

[0036] Furthermore, the Burkholderia mallei strain is a strain with a deposit number of CGMCC NO.27409;

[0037] Preferably, the heating to 60-70°C in (2) can be 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, or 70°C;

[0038] Preferably, the weight ratio of bacteria to phenol in (2) is 1:3-5; it can be 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5; 1:5.

[0039] The present invention has the following beneficial effects:

[0040] 1. The present invention successfully screened out a natural attenuated Burkholderia mallei CVCC67001 with good immunogenicity.

[0041] 2. The present invention extracts and purifies lipopolysaccharide (LPS) from Burkholderia mallei. The iELISA method established using lipopolysaccharide as a coating antigen has a positive compliance rate of 91.67%, which has good antigenicity.

[0042] 3. The present invention prepares the Burkholderia mallei strain CVCC67001 into a preparation and then immunizes animals with the preparation. The preparation is then challenged with Burkholderia mallei. The survival rate of mice in the immunized group is 80%-100%, which proves that the preparation has a good immune protection effect.

[0043] Collection Instructions

[0044] Classification name: Burkholderia mallei, strain number: CVCC67001

[0045] Preservation unit: China Veterinary Drug Administration

[0046] Abbreviation of depository unit: CGMCC

[0047] Address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing

[0048] Deposit date: May 22, 2023

[0049] CGMCC registration number: CGMCC 27409 BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 Gram stain of bacterial colonies

[0051] Figure 2 Colony motility growth chart

[0052] Figure 3 Genetic evolution tree

[0053] Figure 4 Survival curve of mice 28 days after infection DETAILED DESCRIPTION

[0054] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0055] It should be noted that in the present disclosure and particularly in the claims and / or paragraphs, terms such as "comprises", "comprised", "comprising", etc. may have the meanings ascribed to them in Chinese Patent Law; for example, they may mean "includes", "included", "including", etc.; for example, they allow elements not expressly recited but exclude elements found in the prior art or that affect the basic or novel characteristics of the invention.

[0056] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0057] Burkholderia mallei (CVCC67001) was deposited in the General Microbiology Center of China Culture Collection (CGMCC, address: No. 3, Building 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences) on May 22, 2023, with the deposit registration number CGMCC 27409.

[0058] Example 1. Cultivation and biochemical characterization of strains

[0059] 1. Strain screening

[0060] Tissues were extracted from the organs of horses suffering from glanders, spread on glycerol agar medium, and typical single colonies were selected to isolate and select a natural attenuated strain of Burkholderia glanders, which was named CVCC67001.

[0061] 2. Gram staining

[0062] 1) Test methods

[0063] The selected strain CVCC67001 was streaked on a plate containing 4% glycerol TSA medium (purchased from Zhonghai Biotechnology (Zaozhuang) Co., Ltd., item number 101019), and a round, smooth milky white single colony was picked for Gram staining. The bacteria were smeared, fixed, and initially stained with crystal violet stain for 1 minute, and the stain was washed away with water. Iodine solution was added for mordanting for 1 minute, washed with water, decolorized with 95% ethanol, washed with water, and counterstained with diluted carbolic acid fuchsin for about 30 seconds, and washed with water.

[0064] 2) Test results

[0065] Observed under a microscope at 400x, the colonies were red bacilli after Gram staining (see results in Figure 1 ), confirmed that strain CVCC67001 was a Gram-negative bacterium.

[0066] 3. Mobility test

[0067] 1) Test methods

[0068] The screened strain CVCC67001 and Burkholderia pseudomallei (as a control) were streaked on TSA medium containing 4% glycerol, and round, smooth milky white single colonies were picked for puncture culture on SIM dynamic medium (purchased from Haibo Biotechnology Co., Ltd., catalog number HB4112) to observe whether Burkholderia pseudomallei grows along the puncture line in SIM medium.

[0069] 2) Test results

[0070] The strain CVCC67001 grew only along the puncture line on SIM motility medium, confirming that it had no motility (results in Figure 2 ), the control group Burkholderia pseudomallei showed diffuse growth, which confirmed its motility. The motility characteristics confirmed that strain CVCC67001 was Burkholderia pseudomallei, not Burkholderia pseudomallei, which has similar biological characteristics.

[0071] Example 2: Whole genome sequencing and genetic evolution analysis

[0072] 1. Test methods

[0073] The screened strain CVCC67001 and Burkholderia pseudomallei (as a control) were streaked on TSA medium containing 4% glycerol, and a single colony was picked to inoculate 4% glycerol broth medium (purchased from Zhonghai Biotechnology (Zaozhuang) Co., Ltd., catalog number 103018). The live bacterial suspension of strain CVCC67001 was inactivated in a 99°C water bath for 30 min, and bacterial DNA was extracted using the EZNA® Bacterial DNA Kit. Beijing Novogene Biotechnology Co., Ltd. was commissioned to perform sequencing using Illumina NovaSeq PE150 to obtain raw data.

[0074] The genetic evolutionary analysis was performed with the whole genomes of 28 strains uploaded to the NCBI database, and the reference strain was the representative ATCC 23344 strain, and a genetic evolutionary tree was drawn.

[0075] 2. Test results

[0076] The whole genome sequencing results confirmed that the genome of strain CVCC67001 was 5.78 Mb, which was smaller than that of Burkholderia pseudomallei (7.2 Mb) and Burkholderia pseudomallei (6.7 Mb). It encoded 5120 genes with a G+C content of 68.54%, and had different degrees of insertion, deletion, translocation and inversion compared with the ATCC 23344 genome.

[0077] The results of genetic evolution analysis confirmed that strain CVCC67001 was on the L3 branch, but not on the B2 and B3 sub-branches, and had a distant relationship with the Turkish, Indian and Hungarian strains, with no regional overlap; the genetic evolution tree results (see Figure 3 ) confirmed that strain CVCC67001 was a new type of Burkholderia mallei that had not been typed.

[0078] Burkholderia mallei (CVCC67001) was deposited in the General Microbiology Center of China Culture Collection (CGMCC, address: No. 3, Building 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences) on May 22, 2023, with the deposit registration number CGMCC 27409.

[0079] Example 3. Antigenicity determination

[0080] 1. Antigen extraction and purification

[0081] 1) Test methods

[0082] The screened strain CVCC67001 and Burkholderia pseudomallei (as a control) were plated and cultured on TSA medium containing 4% glycerol, and a single colony was picked to inoculate 4% glycerol broth medium (purchased from Zhonghai Biotechnology (Zaozhuang) Co., Ltd., item number 103018) for culture. The pure culture was inactivated and centrifuged, and the supernatant was discarded, which was the wet bacteria. The wet bacteria were weighed, 1 part of the wet bacteria was suspended in 3.4 parts of double distilled water, heated to 66°C, and then 3.8 parts of 66°C 90% (V / V) phenol solution were added, and the mixture was stirred continuously for 15 minutes, and the phenol phase was centrifuged and absorbed. 3 times the volume of methanol containing 1% saturated sodium acetate precooled to -15°C was added, and it was allowed to stand at 4°C for 2 hours, and the supernatant was discarded by centrifugation. Double distilled water was added at 1 / 2 of the volume of the original phenol phase, and it was stirred for 18 hours. The supernatant was collected by centrifugation and stored at 4°C. After adding nuclease (purchased from Beijing Solebow Technology Co., Ltd.) at a final concentration of 15 μg / mL, digestion was carried out at 37°C for 24 h, and then proteinase K (purchased from Beijing Solebow Technology Co., Ltd.) at a final concentration of 15 μg / mL was added and digestion was carried out at 55°C for 3 h, and then digestion was carried out at room temperature for 24 h. The mixture was dialyzed twice with deionized water to obtain lipopolysaccharide LPS.

[0083] The concentration of lipopolysaccharide LPS was selected to be 3-20µg / mL, LPS was used as the coating antigen for 2h at 37℃, 5% BSA was blocked at 37℃ for 2h, serum was diluted 1:500, serum was incubated at 37℃ for 45min, enzyme-labeled goat anti-horse IgG antibody concentration was 1:7500, secondary antibody was incubated at 37℃ for 30min, and color was developed at room temperature in the dark for 10min. The coating concentration with the maximum P / N value was selected as the optimal coating concentration, and 547 clinical horse sera collected from Yunnan, Guangdong, Inner Mongolia Autonomous Region and Beijing were tested, and the compliance rate was calculated compared with the complement fixation test (NY / T557-2021).

[0084] 2) Test results

[0085] When the antigen coating concentration was 10µg / mL, the P / N value was the largest, which confirmed that the LPS extracted and purified from the CVCC67001 strain had good antigenicity.

[0086] surface Optimal antigen coating concentration results (OD450nm)

[0087]

[0088] Compared with the classical diagnostic method of microcomplement fixation test, 547 clinical horse sera were tested, 546 were negative and 1 was positive. Therefore, compared with the microcomplement fixation test, the indirect ELISA detection method established by extracting CVCC67001 strain with LPS as the coating source had a positive coincidence rate of 91.67% (11 / 12) and a negative coincidence rate of 99.82% (546 / 547).

[0089] Table 2 Results of iELISA method established by coating and microcomplement fixation assay for clinical serum

[0090]

[0091] Example 4: Immunization test of Burkholderia pseudomallei (CVCC67001) in mice

[0092] 1. Test methods

[0093] Thirty mice were divided into three groups: one group was immunized (3.3 × 10 3 CFU / ml), immune group II (3.3×10 4CFU / ml)), 10 mice / group; control group (PBS group), 5 mice. 28 days after subcutaneous injection immunization, 5 mice / group in immunization group 1 and immunization group 2 were killed, the mice were dissected, the spleen was taken, 1.0ml PBS was added, the spleen was ground with a grinder, 0.1ml of the suspension was evenly coated on 4% glycerol agar, and cultured at 37℃ for 24 hours, and the number of colonies was calculated to confirm the clearance of the immune strain in the body.

[0094] On the 28th day after immunization, 28.5×10 4 The virulent strain was injected subcutaneously into the surviving mice at a dose of CFU / ml. The surviving mice were dissected 28 days after the infection and the spleens were ground for isolation (the mice were dissected, the spleens were taken out, 1.0 ml PBS was added, the spleens were ground with a grinder, 0.1 ml of the suspension was evenly spread on 4% glycerol agar, and cultured at 37°C for 24 hours) to confirm the immune protection of the immune strain in mice.

[0095] 2. Test results

[0096] 28 days after immunization, the spleens of mice in immunization group 1 and immunization group 2 were sterilely ground and isolated. The residual bacterial count in the spleens of 4 / 4 mice / group was 0 CFU / ml, confirming that the immune strains were completely cleared from the spleens of mice.

[0097] The control group showed obvious rough fur, red and swollen eyelids but no secretions, and slow movements 2 days after the challenge. 2 mice died 3 days after the challenge (2 / 5), 1 mouse died 5 days after the challenge (3 / 5), and 1 mouse died 10 days after the challenge (4 / 5). No mice died 28 days after the challenge, with a mortality rate of 80%. 28 days after the challenge, no mice died in the immunized group, and 1 mouse died in the immunized group 2 (1 / 5). The survival curve was drawn (see the results). Figure 4 The survival rates of the first and second immunization groups were 100% and 80%, respectively, indicating that the CVCC67001 strain as an immune candidate strain has a good immune protection effect against the disease.

[0098] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.

Claims

1. Burkholderia pseudomallei ( Burkholderia mallei ) in the preparation of attenuated vaccine for Burkholderiasis, It is characterized in that The Burkholderia mallei was deposited in the General Microbiology Center of China Culture Collection Administration on May 22, 2023, with the deposit number CGMCC NO.27409.